Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for ARDS?
Current Language EN
English English Türkçe Türkçe Español Español Português Português Pусский Pусский Filipino Filipino Tiếng Việt Tiếng Việt हिन्दी हिन्दी العربية العربية বাংলা বাংলা Deutsch Deutsch 中文 中文

Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for ARDS?

Curtin, Nicola;Bányai, Krisztián;Thaventhiran, James;Le Quesne, John;Helyes, Zsuzsanna;Bai, Péter;
british journal of pharmacology 2020
296
curtin2020repositioningbritish

Abstract

Clinically approved PARP inhibitors (PARPi) have a mild adverse effect profile and are well-tolerated as continuous daily oral therapy. We review the evidence that justifies the repurposing of PARPi to block the proliferation of SARS-CoV-2 and combat the life-threatening sequelae of COVID-19 by several mechanisms. PARPi's can effectively decrease IL-6, IL-1 and TNFα levels (key interleukins in SARS-CoV-2-induced cytokine storm) and can alleviate subsequent lung fibrosis, as demonstrated in murine experiments and clinical trials. PARPi can tune macrophages towards a tolerogenic phenotype. PARPi's may also counteract SARS-CoV-2-induced and inflammation-induced cell death and support cell survival. PARPi's had beneficial effects in animal models of acute respiratory distress syndrome (ARDS), asthma and ventilator-induced lung injury. PARPi's may potentiate the effectiveness of Tocilizumab, Anakinra, Sarilumab, Adalimumab, Canakinumab or Siltuximab therapy. In summary, the evidence suggests that PARPi therapy would benefit COVID-19 patients and trials of these drugs should be undertaken.

Keywords

apoptosis hydroxychloroquine mechanical ventilation adalimumab tocilizumab chloroquine nad+ ards lung fibrosis covid-19 sars-cov-2 lopinavir ritonavir anakinra artd il6 parp parp inhibitor sarilumab siltuximab cytokine release syndrome macrodomain macrophage overactivation syndrome nicotinamide-riboside olaparib remedsivir rucaparib talazoparib

Access

DOI:
10.1111/bph.15137

Citation

ID: 107706
Ref Key: curtin2020repositioningbritish
Use this key to autocite in SciMatic or Thesis Manager

References

References

No Bibliography

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
107706
Unique Identifier:
10.1111/bph.15137
Network:
Scimatic Chain (ID: 481)
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet
Gas fees required in SCI Coins
Buy SCI

Saymatik Web3.0 Wallet

Google Play
App Store